Insights

On May 6, 2025, Gov. Moore approved HB 102/SB 225, which delays the implementation of Maryland’s paid family and medical leave program, known as Maryland Family and Medical Leave Insurance (MD FAMLI), by 18 months. MD FAMLI applies to employers with at least one employee in Maryland. However, employers with fewer than 15 employees are not required to make employer contributions. Contributions have been delayed until January 1, 2027 (previously July 1, 2025). Benefits will now be available to el

On May 15, 2025, the DOL, HHS, and IRS (the departments) issued a statement indicating they will not enforce the MHPAEA 2024 final rule (the 2024 final rule) while they reconsider whether to rescind or modify it. This nonenforcement policy is welcome news for many plan sponsors. However, it does not alleviate their fiduciary obligations to otherwise comply with MHPAEA, including the CAA 2021 nonquantitative treatment limitation (NQTL) comparative analysis requirement. Background On September 9,

On May 8, 2025, in BlueCross BlueShield of Tennessee v. Nicolopoulos, the Sixth Circuit Court of Appeals determined that ERISA did not preempt state law when the defendant, the commissioner of the New Hampshire Insurance Department, sought to enforce state law against the plaintiff, insurance company BlueCross BlueShield of Tennessee. The plaintiff is both the carrier and the fiduciary of a health plan that denied coverage for fertility treatments obtained by a participant in the plan. The poli

On April 9, 2025, in Holland v. Elevance Health Inc., a U.S. District Court in Maine granted a motion to dismiss a putative class action against Elevance Health Inc., which designs and administers a fully insured plan for the Maine Education Association Benefits Trust (MEABT). The plaintiffs in the case alleged that a coverage exclusion for weight-loss medications was a form of disability discrimination in violation of Section 1557 of the ACA, which prohibits discrimination in certain health pr

Libraries have always been hubs of information, learning, and connection — safe spaces where any and all are welcome to pursue knowledge. The workforce that keeps them running is typically detail-oriented, org

The landscape of pharmacy benefit manager (PBM) reform is evolving as healthcare stakeholders grapple with rising prescription drug prices and opaque industry practices.

To understand biosimilars better, let’s break down the basics — brand vs. generic medications. Generic medications are chemically synthesized to be identical to their brand-name counterparts.

With the recent resolution of shortages for GLP-1 medications and their removal from the FDA drug shortage list, medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), the U.S. Food and Drug Administration (FDA)

In today’s labor market, compensation strategy plays a central role in recruiting and retaining talent across the board, but higher education in particular faces unique constraints.